PATENT CLAIM ANALYSIS

Application Number: 16167208
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["424", "490000"]

Abstract:
A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.

Claim (Index 1):
A method for treating attention deficit hyperactivity disorder (ADHD) using a tamper-resistant pharmaceutical dosage form, comprising:\n (a) administering to a person in need of ADHD treatment a tamper-resistant pharmaceutical dosage form, the dosage form comprising:\n a pharmaceutically active compound selected from the group consisting of amphetamine, dex-amphetamine and methylphenidate and their respective pharmaceutically acceptable salts; \n a disintegrant in the amount of about 5 wt. % to about 25 wt. % based on the total weight of the pharmaceutical dosage form; \n polyalkylene oxide in the amount of about 35 wt. % to about 65 wt. % based on the total weight of the pharmaceutical dosage form; \n wherein the pharmaceutically active compound, the disintegrant and the polyalkylene oxide are homogenously mixed in a multitude of particles that exhibit a breaking strength of at least 300N; \n wherein the pharmaceutical dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.; and \n wherein the pharmaceutical dosage form exhibits an increased resistance against solvent extraction compared to particles that are otherwise identical but for the lack of disintegrant.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 2.57692
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15169778', '14287512', '15166573', '13559644', '13223384']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6502101386081565
- 35 USC 102 Novelty (BERT): 0.5189072512334776
- Combined Prediction Score: 0.6370798498706887
- Mean Citation Score: 235.606408
- Max Citation Score: 273.97894
- Similarity Product: 173.1688075298727

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test